Naslov
Single-Dose vs. 3-day Azithromycin in the Treatment of Atypical Pneumonias: Preliminary Results - Poster abstracts

Autori
Schönwald, Slavko ; Kuzman, Ilija ; Škerk, Višnja ; Burek, V. ; Čulig, J. ; Orešković, K.

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo

Izvornik
The Third International Conference on the Macrolides, Azalides and Streptogramins / - , 1996

Skup
The Third International Conference on the Macrolides, Azalides and Streptogramins

Mjesto i datum
Lisabon, Portugal, 24.01.1996. - 26.01.1996

Vrsta sudjelovanja
Poster

Vrsta recenzije
Nije recenziran

Sažetak
An open, randomized study was designed to compare the efficacy and tolerability of single 1.5 g dose of azithromycin (group I) with standard 3-day, 500 mg daily, azithromycin regimen (group II) in the treatment of atypical pneumonia. Up to now, 37 patients (17 in group I and 20 in group II) completed the study and were included in this report. Clinical diagnosis of atypical pneumonia was confirmed by chest X-ray. Serological tests for atypical pathogens were positive in 11 patients in each group: Mycoplasma pneumoniae in 7 and 7, Chlamydia psittaci in 2 and 1, Coxiella burnetii in 1 and 1, Legionella pneumophila in 1 and 2 patients in group I and group II respectively. In remaining 15 patients all serological tests were negative. In both treatment groups all patients became afebrile within 72 hours after treatment with disappearance of symptoms and signs of pneumonia and partial or complete regression of chest X-ray abnormalities within 2 weeks. Tolerability of both dosing regimens was very good and there were no side-effects. Clinically insignificant increase of liver enzymes was observed in 5 and eosinophilia in 1 patient. These preliminary results suggest that standard total dose of azithromycin (1.5 g) may be given as single dose for the outpatient treatment of atypical pneumonia.

Izvorni jezik
Engleski

POVEZANOST RADA